

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

PROFIT WARNING

This announcement is made by Biosino Bio-Technology and Science Incorporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Based on the preliminary review on the unaudited consolidated management accounts of the Group for the year ended 31 December 2024 (the “**Reporting Period**”), the board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record a net loss within a range of RMB55 million to RMB60 million for the Reporting Period as compared with a net loss of approximately RMB19.24 million for the year ended 31 December 2023.

The Board considers that the increase in net loss for the Reporting Period was mainly attributable to (i) a decrease in the gross profit of approximately RMB19.0 million due to a drop in price of products as affected by industry centralised procurement; (ii) a provision for impairment losses on intangible assets, fixed assets and investment properties of approximately RMB13.0 million during the Reporting Period, as compared with approximately RMB0.6 million for the corresponding period in 2023; and (iii) a provision for impairment losses on trade and bills receivables and other receivables of approximately RMB6.5 million during the Reporting Period, as compared with approximately RMB0.7 million for the corresponding period in 2023.

The information contained in this announcement is only a preliminary assessment by the management of the Company based on the unaudited consolidated management accounts of the Group for the Reporting Period and the information currently available to the Board, which have not been audited by the auditor of the Company or reviewed by the audit committee of the Company. The Company is in the process of finalising the annual results of the Group for the Reporting Period, which is expected to be published on 31 March 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Zhengyong
Vice Chairman and Executive Director

Beijing, the People's Republic of China
20 March 2025

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairman and executive Director

Mr. Chen Zhengyong (陳正永先生)

Vice chairman and non-executive Director

Mr. Yang Peng (楊鵬先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生), Prof. Shen Jiangang (沈劍剛教授) and Dr. He Xin (何欣博士)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.